1. "Melanoma and Immunotherapeutics Service"
Formats
  1. Journal Article (954)
  2. Meeting Abstract (771)
  3. Book Section (42)
  4. Editorial (32)
  5. Review (26)
  6. Research Letter (15)
  7. Guidelines (6)
  8. Correspondence (5)
  9. Conference Paper (4)
  10. Miscellaneous (3)
  11. Book Whole (2)
Groups
  1. Department of Medicine (1860)
  2. Melanoma and Immunotherapeutics Service (1860)
  3. Solid Tumor Oncology Division (1860)
  4. GSK Faculty (1050)
  5. Melanoma Disease Management Team (782)
  6. Hematologic Malignancies, Division of (507)

More Groups

People
  1. Jedd Wolchok (905)
  2. Taha Merghoub (364)
  3. Michael Postow (361)
  4. Paul Chapman (326)
  5. Alexander Shoushtari (244)
  6. Margaret Callahan (197)

More People

Years
  1. 2025 (22)
  2. 2024 (46)
  3. 2023 (66)
  4. 2022 (125)
  5. 2021 (112)
  6. 2020 (122)

More Years

Publications
  1. Journal of Clinical Oncology (330)
  2. Journal for ImmunoTherapy of Cancer (131)
  3. Cancer Research (106)
  4. Clinical Cancer Research (90)
  5. Annals of Oncology (77)
  6. Proceedings of the American Association for Cancer Research Annual Meeting (43)

More Publications

Publishers
  1. American Society of Clinical Oncology (342)
  2. American Association for Cancer Research (274)
  3. Biomed Central Ltd (148)
  4. Elsevier Inc. (144)
  5. Oxford University Press (109)
  6. Nature Publishing Group (88)

More Publishers

Results (1860)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab
    Journal Article

    Chapman, P. B.; Jayaprakasam, V. S.; Panageas, K. S.; Callahan, M.; Postow, M. A.; Shoushtari, A. N.; Wolchok, J. D.; Betof Warner, A.
    Journal for ImmunoTherapy of Cancer (2021)

    Fulltext@MSK | Save
  • Dynamic biomarkers of response to anti-immune checkpoint inhibitors in cancer
    Editorial

    Dermime, S.; Merhi, M.; Merghoub, T.
    Frontiers in Immunology (2021)

    Fulltext@MSK | Save
  • Isoform specific anti-TGFβ therapy enhances antitumor efficacy in mouse models of cancer
    Journal Article

    Gupta, A.; Budhu, S.; Fitzgerald, K.; Giese, R.; Michel, A. O.; Holland, A.; Campesato, L. F.; van Snick, J.; Uyttenhove, C.; Ritter, G.; more...
    Communications Biology (2021)

    Fulltext@MSK | Save
  • Early use of high-dose glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy
    Journal Article

    Bai, X.; Hu, J.; Betof Warner, A.; Quach, H. T.; Cann, C. G.; Zhang, M. Z.; Si, L.; Tang, B.; Cui, C.; Yang, X.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • TMB and inflammatory gene expression associated with clinical outcomes following immunotherapy in advanced melanoma
    Journal Article

    Hodi, F. S.; Wolchok, J. D.; Schadendorf, D.; Larkin, J.; Long, G. V.; Qian, X.; Saci, A.; Young, T. C.; Srinivasan, S.; Chang, H.; more...
    Cancer Immunology Research (2021)

    Fulltext@MSK | Save
  • Early reduction in ctDNA, regardless of best RECIST response, is associated with overall survival (OS) on tebentafusp in previously treated metastatic uveal melanoma (mUM) patients
    Meeting Abstract

    Shoushtari, A. N.; Collins, L.; Espinosa, E.; Sethi, H.; Stanhope, S.; Abdullah, S.; Ikeguchi, A.; Ranade, K.; Hamid, O.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A phase II, open-label, multi-dose study of [89Zr]Zr-Df-IAB22M2C (CD8 cell PET tracer) PET/CT in patients with selected advanced or metastatic solid malignancies scheduled to receive standard of care immunotherapy, as single agent or in combination
    Meeting Abstract

    Margolin, K. A.; Korn, R.; Farwell, M.; Postow, M. A.; Hays, D.; Wilson, I. A.; Le, W. H.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • A pilot study of engineered adenovirus ONCOS-102 in combination with pembrolizumab (pembro) in checkpoint inhibitor refractory advanced or unresectable melanoma
    Meeting Abstract

    Shoushtari, A. N.; Olszanski, A. J.; Nyakas, M.; Hornyak, T. J.; Wolchok, J. D.; Levitsky, V.; Møller, A. S.; Kuryk, L.; Handeland, K. R.; Jäderberg, M.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Investigational (Inv) agents with or without pembrolizumab (pembro) or pembro alone in melanoma (mel): KEYMAKER-U02
    Meeting Abstract

    Dummer, R.; Long, G. V.; Pavlick, A. C.; Postow, M. A.; Ribas, A.; Robert, C.; Scolyer, R. A.; Taube, J. M.; Tetzlaff, M.; Su, S. C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • CheckMate 204: 3-year outcomes of treatment with combination nivolumab (NIVO) plus ipilimumab (IPI) for patients (pts) with active melanoma brain metastases (MBM)
    Meeting Abstract

    Tawbi, H. A.; Forsyth, P. A.; Hodi, F. S.; Algazi, A.; Hamid, O.; Lao, C. D.; Moschos, S. J.; Atkins, M. B.; Lewis, K.; Postow, M. A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save